DexCom earnings beat by $0.03, revenue topped estimates
In recent transactions disclosed by Vivani Medical (TASE:BLWV), Inc. (NASDAQ:VANI), Gregg Williams, a director and significant shareholder of the company, acquired additional shares of the company’s common stock. The purchases, made over two days, include 2,000 shares bought at $1.01 per share on April 2 and 22,939 shares at $1.00 per share on April 3. The total value of these transactions amounts to $24,959.
Following these acquisitions, Williams now holds a direct ownership of 4,720,800 shares. Additionally, he has indirect control over 13,677,308 shares through various trusts and entities, including the Gregg G. Williams 2006 Trust and Williams International Co. LLC, among others. These transactions reflect Williams’ ongoing investment in Vivani Medical, a company specializing in electromedical and electrotherapeutic apparatus.
In other recent news, Vivani Medical, Inc. reported its 2024 financial results, revealing a net loss of $23.5 million, or $0.43 per share, aligning closely with analyst expectations. The company has also secured $8.25 million through a private placement to advance its drug implant development, specifically focusing on its NPM-139 and NPM-115 implants. H.C. Wainwright has maintained a Buy rating on Vivani Medical with a $4.00 price target, reflecting confidence in the company’s pipeline. Vivani Medical’s NPM-115 implant has reached full enrollment in its Phase 1 LIBERATE-1 trial, a critical step forward in its clinical development. Additionally, promising preclinical results for the NPM-139 implant showed significant weight loss in rats, highlighting its potential for chronic weight management. The LIBERATE-1 trial is expected to deliver topline results by mid-2025, providing further insights into the implant’s effectiveness. Vivani Medical is utilizing its NanoPortal™ platform to develop long-acting GLP-1 implants, aiming to improve medication adherence and reduce treatment burdens. The company is leveraging Australian research and development rebates to offset clinical trial costs, with data expected to meet U.S. FDA standards.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.